Inhibition of mammary tumor growth using lysyl oxidase-targeting nanoparticles to modify extracellular matrix

Mathumai Kanapathipillai; Akiko Mammoto; Tadanori Mammoto; Joo H Kang; Elisabeth Jiang; Kaustabh Ghosh; Netanel Korin; Ashley Gibbs; Robert Mannix; Donald E Ingber

doi:10.1021/nl301206p

Inhibition of mammary tumor growth using lysyl oxidase-targeting nanoparticles to modify extracellular matrix

Nano Lett. 2012 Jun 13;12(6):3213-7. doi: 10.1021/nl301206p. Epub 2012 May 10.

Authors

Mathumai Kanapathipillai¹, Akiko Mammoto, Tadanori Mammoto, Joo H Kang, Elisabeth Jiang, Kaustabh Ghosh, Netanel Korin, Ashley Gibbs, Robert Mannix, Donald E Ingber

Affiliation

¹ Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, Massachusetts 02115, United States.

PMID: 22554317
DOI: 10.1021/nl301206p

Abstract

A cancer nanotherapeutic has been developed that targets the extracellular matrix (ECM)-modifying enzyme lysyl oxidase (LOX) and alters the ECM structure. Poly(d,l-lactide-co-glycolide) nanoparticles (∼220 nm) coated with a LOX inhibitory antibody bind to ECM and suppress mammary cancer cell growth and invasion in vitro as well as tumor expansion in vivo, with greater efficiency than soluble anti-LOX antibody. This nanomaterials approach opens a new path for treating cancer with higher efficacy and decreased side effects.

Publication types

Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

Animals
Cell Line, Tumor
Cell Proliferation / drug effects*
Extracellular Matrix / drug effects*
Mammary Neoplasms, Experimental / drug therapy*
Mammary Neoplasms, Experimental / pathology*
Mice
Nanocapsules / administration & dosage*
Protein-Lysine 6-Oxidase / administration & dosage*

Substances

Nanocapsules
Protein-Lysine 6-Oxidase